Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
830 stopped studies mapped to Genitourinary System Carcinoma and descendants · 90% state a reason
Over the 830 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01712685 | Imaging Studies of Kidney Cancer Using 18F-VM4-037 | Phase 2 | terminated | Oct 23, 2012 | National Cancer Institute (NCI) | Study was closed to accrual because imaging agent was no longer available. | Enrollment / accrual |
| NCT02410174 | To Evaluate Stereotactic Body Radiotherapy for Treatment of Primary Renal Cell Carcinoma… | Phase 1 | terminated | Apr 7, 2015 | Beth Israel Medical Center | Poor Accural | Other (stated, no rule matched) |
| NCT01521143 | Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete…(CANVAS) | Phase 2 | terminated | Jan 30, 2012 | Prima BioMed Ltd | The study was terminated due to company restructuring and changes in drug development priorities. | Sponsor / business decision |
| NCT00598858 | Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the…(2007-5904) | Phase 2 | withdrawn | Jan 23, 2008 | John P. Fruehauf | Halted due to zero accrual and lack of funding | Enrollment / accrual |
| NCT02035345 | Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment | Phase 4 | terminated | Jan 14, 2014 | Massachusetts General Hospital | Extended Carboplatin Infusion did not Reduce Frequency of Hypersensitivity Reactions | Other (stated, no rule matched) |
| NCT00565227 | Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and… | Phase 1 | terminated | Nov 29, 2007 | University of Michigan Rogel Cancer Center | closed due to toxicity | Safety / toxicity |
| NCT01144169 | Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma | Phase 1 | terminated | Jun 15, 2010 | University of Pittsburgh | barriers to accrual: delay until surgery and additional pre-operative visits | Enrollment / accrual |
| NCT00061178 | Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma | Phase 3 | withdrawn | May 23, 2003 | Genentech, Inc. | No patients were enrolled, study cancelled before start | Enrollment / accrual |
| NCT02279576 | Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG)(PAZOPEN-SOGUG) | Phase 2 | terminated | Oct 31, 2014 | Spanish Oncology Genito-Urinary Group | The low recruitment of patients will not allow to complete the study with the required number of… | Enrollment / accrual |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | Phase 1 | terminated | Apr 11, 2013 | Mirna Therapeutics, Inc. | Five immune related serious adverse events | Safety / toxicity |
| NCT02083536 | LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma | Phase 1 | withdrawn | Mar 11, 2014 | University of Miami | Study voluntarily stopped by Principal Investigator due to lack of accrual. | Investigator |
| NCT00318110 | Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma | Phase 2 | terminated | Apr 26, 2006 | Center for International Blood and Marrow Transplant Research | Unable to meet subject enrollment goal. | Enrollment / accrual |
| NCT02627430 | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced… | Phase 1 | withdrawn | Dec 11, 2015 | National Cancer Institute (NCI) | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT01326390 | Impact of C-arm CT in Decreased Renal Function Undergoing TACE for Tx of Hepato-Cellular… | — | terminated | Mar 30, 2011 | Stanford University | not stated | Not stated |
| NCT02140138 | An Open Label Randomised Trial of RNActive® Cancer Vaccine in High Risk and Intermediate… | Phase 2 | terminated | May 16, 2014 | CureVac | Recruitment was terminated after enrolment of 35 instead of 36 evaluable patients for… | Enrollment / accrual |
| NCT01981707 | F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer(PRECHOL) | Phase 2 / Phase 3 | terminated | Nov 11, 2013 | University Hospital, Grenoble | enrollment default | Enrollment / accrual |
| NCT02718742 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy… | Phase 2 | withdrawn | Mar 24, 2016 | Mayo Clinic | not stated | Not stated |
| NCT02479178 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical…(iNSITE2) | Phase 2 | terminated | Jun 24, 2015 | BIND Therapeutics | not stated | Not stated |
| NCT00556205 | Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma | Phase 2 | withdrawn | Nov 9, 2007 | Massachusetts General Hospital | Toxicity of combination from other trials | Safety / toxicity |
| NCT00440973 | Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With… | Phase 2 | terminated | Feb 27, 2007 | The Methodist Hospital Research Institute | contract issues | Other (stated, no rule matched) |
| NCT00522249 | Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC | Phase 1 / Phase 2 | terminated | Aug 29, 2007 | The Methodist Hospital Research Institute | PI decision | Other (stated, no rule matched) |
| NCT02307474 | A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer | N/A | withdrawn | Dec 4, 2014 | Case Comprehensive Cancer Center | Funding Unavailable | Funding |
| NCT02014831 | Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE)(PENILANE) | Phase 2 | withdrawn | Dec 18, 2013 | Centre Leon Berard | Industry decline to supply study drug | Drug supply |
| NCT02470559 | Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients… | Phase 1 | withdrawn | Jun 12, 2015 | Barbara Ann Karmanos Cancer Institute | Study did not accrue any participants, the PI has left the institution. | Enrollment / accrual |
| NCT02130947 | Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer… | N/A | withdrawn | May 6, 2014 | UNC Lineberger Comprehensive Cancer Center | We were not able to accrue any participants. | Enrollment / accrual |
| NCT01762033 | A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma | Phase 2 | terminated | Jan 7, 2013 | Lpath, Inc. | not stated | Not stated |
| NCT01840943 | A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial… | Phase 3 | terminated | Apr 26, 2013 | Xian-Janssen Pharmaceutical Ltd. | the study was terminated due to medication supply issue from current manufacturer | Drug supply |
| NCT01771003 | Remote Ischemia Pre-Conditioning in Patients Undergoing Partial Nephrectomy | N/A | terminated | Jan 18, 2013 | University Health Network, Toronto | not stated | Not stated |
| NCT00480935 | A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma | Phase 2 | terminated | May 31, 2007 | University Health Network, Toronto | poor recruitment | Enrollment / accrual |
| NCT00913913 | Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell… | Phase 2 | terminated | Jun 4, 2009 | Dartmouth-Hitchcock Medical Center | low accrual not allowing site to meeting statistical endpoints | Enrollment / accrual |
| NCT00313612 | Oxaliplatin and Topotecan in Advance Ovarian Cancer | Phase 2 | terminated | Apr 12, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01977586 | Functional Imaging in the Assessment of mRCC Response to Sunitinib | N/A | withdrawn | Nov 6, 2013 | Imperial College Healthcare NHS Trust | Difficulty in recruiting suitable patients at centre | Enrollment / accrual |
| NCT02396368 | A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic…(Radium-223) | Phase 1 | withdrawn | Mar 24, 2015 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase III study results for the drug Tesquinimod were not promising so it was a drug development… | Other (stated, no rule matched) |
| NCT02024685 | Treatment Decision Analysis Model for Prostate Cancer: A Randomized Trial | N/A | terminated | Dec 31, 2013 | Case Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT02042885 | A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With… | Phase 1 / Phase 2 | terminated | Jan 23, 2014 | Otsuka Novel Products GmbH | not stated | Not stated |
| NCT01342627 | Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma(SERCC) | Phase 2 | terminated | Apr 27, 2011 | Centro di Riferimento Oncologico - Aviano | low enrollment rate | Enrollment / accrual |
| NCT01100242 | Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma | Phase 2 | terminated | Apr 8, 2010 | New Mexico Cancer Research Alliance | Low accrual | Enrollment / accrual |
| NCT01368003 | STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor… | Phase 2 | withdrawn | Jun 7, 2011 | Toni Choueiri, MD | Loss of funding. | Funding |
| NCT01071928 | Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma | Phase 2 | withdrawn | Feb 19, 2010 | Hoosier Cancer Research Network | Lack of efficacy of experimental treatment | Efficacy / futility |
| NCT00574483 | Treatment of Advanced Renal Cell Carcinoma With Quinacrine | Phase 2 | withdrawn | Dec 17, 2007 | Cleveland BioLabs | reevaluation of compound development | Other (stated, no rule matched) |
| NCT01561482 | Study of Metformin With Simvastatin for Men With Prostate Carcinoma | Phase 2 | withdrawn | Mar 23, 2012 | Nicholas Mitsiades | Study closed due to slow/low enrollment; no subjects were enrolled. | Enrollment / accrual |
| NCT01175772 | Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment… | Phase 2 | terminated | Aug 5, 2010 | HaEmek Medical Center, Israel | Due to change in the national policy of medications | Other (stated, no rule matched) |
| NCT00176280 | Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in… | Phase 2 | withdrawn | Sep 15, 2005 | University of Kentucky | Slow accrual | Enrollment / accrual |
| NCT00053235 | Research Study in Patients With Advanced Ovarian Epithelial Cancer | — | withdrawn | Jan 28, 2003 | Gynecologic Oncology Group | not stated | Not stated |
| NCT01200797 | SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian… | Phase 2 | terminated | Sep 14, 2010 | National Cancer Institute (NCI) | Slow accrual was the reason for study termination. | Enrollment / accrual |
| NCT01198535 | Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer | Phase 1 | terminated | Sep 10, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02235324 | Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in… | Phase 2 | withdrawn | Sep 9, 2014 | University of Southern California | Lack of funding | Funding |
| NCT01507740 | Profile of Soluble and Cellular Biomarkers and of Functional Imaging During… | — | terminated | Jan 11, 2012 | Medical University Innsbruck | Study was stopped 04.10.2014 prematurly after recruitment of HCC and RCC patients. NSCLC (2 of 10… | Enrollment / accrual |
| NCT00930345 | Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic…(PREINSUT) | Phase 4 | terminated | Jun 30, 2009 | Assistance Publique - Hôpitaux de Paris | not stated | Not stated |
| NCT01732432 | Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC)(EAOC) | — | withdrawn | Nov 22, 2012 | University Hospital, Basel, Switzerland | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jan 11, 2017source: clinicaltrials